Biotech Blueprint
Subscribe
Sign in
Home
Notes
This Week in Biotech
Deep Dives
Consulting
Archive
About
This Week in Biotech
Latest
Top
Discussions
The best small cell lung cancer data in 30 years, and the argument over whether to believe It – This Week in Biotech #118
Two B7-H3 antibody drug conjugates cut death risk 54% in relapsed SCLC, Gilead and Merck's trial only worked in Chinese patients, and Novartis loses its…
Sep 18
•
Katerina Roznik
10
1
1
Novartis had the worst day in its history and the FDA approved a drug its advisers rejected, again – This Week in Biotech #117
Pelacarsen misses in 8,323 patients, del-desiran fails five months after a $12B acquisition, and the FDA approves a drug its own advisers voted 6-3…
Sep 11
•
Katerina Roznik
8
FDA official overruled her own review team to approve Replimune’s drug – This Week in Biotech #116
Internal memos reveal how Tudriqev got approved, three undisclosed deaths in Chinese trials trigger an FDA response, and Ultragenyx’s Angelman drug…
Sep 4
•
Katerina Roznik
8
1
1
FDA Approves a Pancreatic Cancer Drug in 35 Days – This Week in Biotech #115
Revolution Medicines’ Rasonque doubles survival in metastatic pancreatic cancer, Most favored nation pricing deals reach mid cap biotech, and Genentech…
Aug 28
•
Katerina Roznik
10
2
Moderna gains 176% in a day on a melanoma vaccine trial – This Week in Biotech #114
Merck-Moderna's mRNA cancer vaccine hits Phase 3, three patient deaths surface in Chinese trials, and Trump nominates a new FDA commissioner (Aug 14-20…
Aug 21
•
Katerina Roznik
8
NEJM retracts a registrational trial for the first time, plus Trump's childhood vaccine executive order – This Week in Biotech #113
Amgen's Tavneos pivotal study pulled after 9 patient endpoints were changed post-unblinding, Jazz buys Actio Biosciences, and Replimune's approval label…
Aug 14
•
Katerina Roznik
7
FDA Approves Moderna's mRNA Flu Vaccine, Takeda's Orzeyful, and Replimune's Tudriqev – This Week in Biotech #112
Three first-in-class approvals in seven days, Lilly's $23B quarter crushes Novo again, and a rumored $400B AstraZeneca-Bristol Myers merger knocks 9…
Aug 7
•
Katerina Roznik
4
argenx's $2.2B Immunology Buy, J&J's In Vivo CAR-T Bet, and the FDA's Adcomm Revival – This Week in Biotech #111
argenx pays 86% premium for Forte's CD122 antibody, J&J commits $785M on in vivo CAR-T, and FDA panels turn on Capricor and Replimune (7/24-7/30, 2026).
Jul 31
•
Katerina Roznik
13
2
Retatrutide Underdelivers, Novo Sues Lilly, and GSK Wins a Fast Lung Cancer Approval – This Week in Biotech #110
Lilly's triple agonist misses on cardiovascular outcomes, Novo Nordisk takes Lilly to court over "deceptively false" ads, and Trump threatens 200…
Jul 24
•
Katerina Roznik
12
Merck's Oral PCSK9 Cholesterol Pill, Lilly's $2.8B Psychedelics Buy, and Makary's Regulatory Ghost – This Week in Biotech #109
Lipfendra becomes the first oral drug to match injectable cholesterol lowering, Lilly enters psychedelics with an $2.8B AtaiBeckley acquisition, and the…
Jul 17
•
Katerina Roznik
20
2
4
AstraZeneca's Amyloid Miss, Vertex's $10B Crinetics Buy, and Kidney Disease's Two-Drug Race – This Week in Biotech #108
Eplontersen fails in a market its competitors already own, Vertex makes its biggest deal ever to diversify beyond cystic fibrosis, and Vera Therapeutics…
Jul 10
•
Katerina Roznik
9
Happy 4th of July – This Week in Biotech #107
Roche beats two KRAS drugs at once, Anthropic starts making its own drugs, and biotech's XBI hits a five year high (June 26-July 2, 2026).
Jul 3
•
Katerina Roznik
11
1
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
